For years, people with long COVID have been told their crushing fatigue is “just stress” or “in their head.” New brain imaging suggests otherwise — and the real cause may be hiding in a part of your brain most people have never heard of.
A Diagnosis Nobody Could See — Until Now
Ask anyone living with long COVID what the hardest part is, and many won’t say the fatigue itself. They’ll say the disbelief. The blood tests come back normal. The MRI looks fine. And yet they can’t get through a workday, can’t remember why they walked into a room, can’t summon the will to do things they used to enjoy. For half a decade, that gap between how people feel and what doctors can measure has been the defining frustration of the condition.
That gap may have just gotten a lot smaller.
A new brain imaging study led by researchers at the Centre for Addiction and Mental Health, published in the journal eBioMedicine, provides what its authors describe as the strongest evidence to date that long COVID is associated with injury to dopamine-releasing neurons in the brain. The findings offer a biological explanation for some of the condition’s most stubborn symptoms — fatigue, brain fog, memory trouble, and a strange, hollowed-out lack of motivation — and, more importantly, a potential target for actual treatment. Medical Xpress
This isn’t a small, easily-dismissed pilot study buried in an obscure journal. It’s the product of years of work by one of the world’s leading centres for brain imaging research, and it directly answers a question that has haunted long COVID research since the pandemic began: is something in the brain actually broken, or is this psychological?
The answer, it turns out, is neither simple nor comforting — but it is, for the first time, measurable.
The Brain Region Nobody’s Heard Of: The Striatum
To understand what researchers found, you need to understand a part of the brain called the striatum. It’s not a region most people encounter outside a neuroscience textbook, but it does an enormous amount of quiet, unglamorous work. The striatum plays a central role in motivation, movement, learning, and cognition — essentially, it’s the machinery behind your ability to want to do things, to move your body smoothly, and to think clearly enough to get through a day. Inside Precision Medicine
The striatum runs on dopamine. Not the “reward chemical” dopamine of pop psychology — though that’s part of it — but a broader signaling system that governs how much energy and drive your brain assigns to any given task. When that system is compromised, you don’t necessarily feel sad. You feel depleted. Getting up feels like wading through wet cement. Thoughts arrive late, or not at all. Your body moves a half-beat slower than it used to.
That description will sound uncomfortably familiar to millions of people with long COVID.
Researchers had a hunch that dopamine might be involved for a specific biological reason. Dopaminergic neurons are known to be vulnerable to injury from gliosis, a form of brain inflammation, and they carry a particularly high density of ACE2 receptors — the exact receptor that SARS-CoV-2 uses to enter cells in the first place. In other words, dopamine neurons may sit right in the blast radius of the virus’s preferred entry point. But until now, nobody had actually looked. nih
How Scientists Looked Inside a Living Brain
You can’t biopsy a living person’s brain to count their dopamine neurons. So researchers used the next best thing: a specialized form of PET (positron emission tomography) imaging that can track a specific protein called VMAT2 — short for vesicular monoamine transporter 2.
Think of VMAT2 as a packaging system. Dopamine neurons use it to load dopamine into tiny capsules before releasing it into the brain. VMAT2 density indicates how many functioning dopamine nerve terminals a given brain region has — so measuring VMAT2 is, in effect, a way of counting how much of the brain’s dopamine-releasing machinery is intact and working. Martin Cid Magazine
The case-control study, conducted in Toronto between August 2022 and April 2025, examined 24 adults with long COVID and 24 age-matched healthy controls, with the healthy control group later extended to 43 participants for additional analysis. Each participant underwent PET scanning to measure VMAT2 binding across three specific sections of the striatum: the ventral striatum, the dorsal putamen, and the dorsal caudate. nih
The results were striking. The team found significantly lower levels of the imaging marker — indicating reduced dopamine nerve terminal density — across all major regions of the striatum. This wasn’t a subtle, statistically-massaged difference. It was a consistent, measurable deficit showing up across multiple brain regions in people who, before COVID, had no such symptoms. Medical Xpress
Matching the Damage to the Symptoms
Here’s where the study moves from interesting to genuinely important: the location of the damage lined up with the specific symptoms patients had been reporting all along.
Reductions in the ventral striatum correlated with a lack of motivation and fatigue, while changes in the dorsal putamen were linked to slowed movement, and losses in the caudate putamen tracked with memory problems. Each region of dopamine loss corresponded almost precisely to a different, previously unexplained symptom cluster. Inside Precision Medicine
This matters enormously for how the condition gets understood — clinically and socially. Long COVID has often been described in vague, catch-all terms because its symptoms are so wide-ranging and inconsistent from patient to patient. This study suggests that variability might not be randomness at all. It might reflect which specific part of the dopamine system got hit hardest in a given person. Someone whose ventral striatum took the brunt of the damage might struggle most with motivation and drive. Someone with more putamen involvement might notice their movements feel sluggish or uncoordinated. Someone with caudate involvement might feel like their memory has quietly gone missing.
For the first time, brain-imaging researchers have identified specific neuron damage — specific cells, specific brain locations, specific symptoms — in patients who have been told for years there was nothing measurable to find. That sentence alone is likely to land hard for a lot of people who’ve spent years being told, in one polite phrasing or another, that it was probably anxiety. Martin Cid Magazine
“For Five Years I Have Been Seeking Answers”
Behind the PET scans and striatal subregions are real people who have spent years without a name for what’s happening to them. One of the study’s lived-experience research advisors, Susan Deuville, has said that for five years she has been seeking answers about what happened to her after contracting COVID in 2021. ScienceDaily
That five-year wait is not unusual. Long COVID is estimated to affect roughly 5% of the world’s population, and approximately nine million adults in the United States alone — making it, by sheer numbers, one of the most common chronic conditions to come out of the pandemic. And yet, until this study, the biological “why” behind its most disabling symptoms had remained frustratingly out of reach. Medical XpressInside Precision Medicine
The condition is defined by a wide range of persistent, sometimes debilitating symptoms — including fatigue, brain fog, memory problems, and low mood — that continue for at least three months after the initial COVID-19 infection. What’s made long COVID especially hard to treat is precisely what this study starts to chip away at: no evidence-based treatments currently exist, largely because of how limited our understanding of the underlying brain pathology has been. Medical XpressMedical Xpress
You can’t design a targeted treatment for a mechanism you can’t see. That’s what makes this study different from the dozens of long COVID papers that have come before it — it doesn’t just describe symptoms; it points, for the first time, at a specific, physical system that appears to be malfunctioning.
Building on Years of Inflammation Research
This discovery didn’t come out of nowhere. Earlier work from the same research group had already shown that people with long COVID have elevated levels of inflammation in brain regions rich in dopamine, which planted an obvious question: is that inflammation just background noise, or is it actually damaging the neurons that live there? Technology Networks
Previous research in this area had mostly focused on inflammation and changes in brain metabolism, but researchers still lacked direct evidence of injury to the dopamine pathway itself. This new study was specifically designed to close that gap — to move from “there’s inflammation nearby” to “the neurons themselves show measurable injury.” A review of the existing scientific literature up to November 2025 confirmed that no prior studies had directly examined whether the brain’s dopamine-producing neurons were affected in long COVID. Technology Networksnih
In other words, this is the missing piece researchers had been chasing for roughly three years — the moment where circumstantial evidence turned into a direct hit.
What This Doesn’t Prove Yet
It’s worth being honest about the limits of the findings, because overselling early research is exactly what erodes trust in science — and this study’s authors have been careful not to do that.
The scans represent patients at a single point in time; without baseline pre-infection scans or sequential follow-up imaging, the data can’t show whether dopamine nerve density recovers over time, stabilizes, or continues to decline. That’s a meaningful unknown. It means researchers currently can’t tell someone with long COVID whether their brain is likely to heal on its own, hold steady, or worsen. That uncertainty is uncomfortable, but it’s also exactly why the next phase of research matters so much. Martin Cid Magazine
There’s also the standard caveat that comes with any imaging study of this size: the primary group studied included 24 adults with long COVID compared against 24 age-matched controls. That’s a solid, carefully controlled sample for this kind of specialized PET imaging — which is expensive and logistically demanding to run — but it’s not yet the kind of large-scale, multi-site study that would let researchers say with total confidence how universal this pattern is across the full, wildly diverse population of long COVID patients. nih
Correlation versus causation is another open question. The study shows that dopamine neuron loss and specific symptoms track together — it doesn’t yet prove, with total certainty, that fixing the dopamine deficit will fix the symptoms. That’s precisely what happens next.
The Next Step: An Actual Clinical Trial
This is the part of the story that turns a fascinating discovery into something people living with long COVID can actually watch unfold in real time.
Building on these results, the investigators plan to launch a clinical trial in collaboration with University Health Network to evaluate whether therapies that improve dopamine function can reduce fatigue, improve motivation, and enhance memory in people with long COVID. If the trial succeeds, it could pave the way for one of the first mechanism-based treatment approaches for the condition — meaning a treatment built around why the symptoms are happening, rather than one that simply tries to manage symptoms individually with no clear target. Inside Precision MedicineInside Precision Medicine
A positive response to dopamine-targeted therapy in that trial would itself be meaningful evidence — it would suggest the dopamine system retains enough underlying function to respond to pharmacological support, rather than being permanently and irreversibly damaged. Results from that trial are expected in 2027. Martin Cid MagazineMartin Cid Magazine
That timeline might feel distant if you’re living with symptoms right now. But for a condition that has had essentially zero evidence-based treatment options since it was first recognized, a concrete, mechanism-driven trial with a defined endpoint is a genuinely significant development.
Why This Study Changes the Conversation
Beyond the science itself, there’s a cultural shift buried in this research that’s arguably just as important as the neurons it identifies.
For years, the absence of visible abnormalities on standard brain scans has been quietly weaponized — by skeptical doctors, by insurance systems, by employers, sometimes even by well-meaning family members — to suggest that long COVID symptoms were exaggerated, psychological, or simply not “real” in a medical sense. That framing has caused enormous harm, delaying care and compounding the isolation that comes with a chronic, invisible illness.
A study identifying specific, localized neuron damage that lines up precisely with specific, previously “unexplainable” symptoms pulls the rug out from under that skepticism. It doesn’t erase the difficulty of the condition. If anything, it confirms just how physically real the difficulty is. The specific loss of dopamine-releasing neurons directly correlates with patient symptoms — this is not a subjective self-report being taken at face value; it’s an objective, quantifiable finding sitting inside a peer-reviewed medical journal. World Today News
For the millions of people whose lives have been reshaped by long COVID, that validation, paired with an actual pathway toward treatment, may be the first real reason for cautious optimism this condition has offered in years.
What to Watch Next
If you or someone you know is living with long COVID, there’s nothing to do differently today — this research hasn’t yet produced an approved treatment, and dopamine-related therapies used for other conditions shouldn’t be self-administered off-label based on a single study. But there are a few developments worth watching over the next year or two:
- Whether the CAMH-University Health Network clinical trial confirms that dopamine-targeting therapies actually improve fatigue, motivation, and memory in long COVID patients.
- Whether larger, multi-site imaging studies replicate the striatal dopamine findings across more diverse patient populations.
- Whether follow-up scans of the same patients over time reveal whether this kind of neuron damage can heal, or whether early intervention becomes critical.
For a condition that has spent years without a clear biological signature, having a specific, testable hypothesis — dopamine neuron injury in the striatum — represents real forward motion. It won’t resolve long COVID overnight. But for the first time, researchers aren’t just describing what patients are experiencing. They’re starting to show, cell by cell, why.
